

Research Activities Newsletter

March and April 2022

In the News: Congratulations to the following awardees



Katherine Balantekin, Clinical Assistant Professor of Exercise and Nutrition Sciences received a continuation award from the National Institute of Diabetes and Digestive and Kidney Diseases/NIH for the project entitled, *The Intersection between Loss of Control Eating and Obesity: The Role of Restriction and Food Reinforcement*. The project will continue to explore the relationships among LOC eating, parental restriction, and RRV of HED food with respect to obesity risk in a sample of 7–10-year-old children at risk for obesity.



Hailey Banack, Research Assistant Professor of Epidemiology & Environmental Health, is PI on a new award from The National Cancer Institute/NIH for the project entitled, *Ms. LILAC: Muscle Mass in the Life and Longevity After Cancer (LILAC) Study*. The study will provide the first-ever direct measure of muscle mass in a large sample of community dwelling postmenopausal women using the D-3 creatine method. The results will contribute to the development of public health recommendations and intervention strategies to prevent low muscle mass and associated adverse health outcomes in older and long-term cancer survivors. Co-Investigators from EEH include **Jean Wactawski-Wende**, Dean of SPHHP and SUNY Distinguished Professor, and **Heather Ochs-Balcom**, Associate Professor.



David Hostler, Professor and Chair of Exercise and Nutrition Science, is PI on a continuation award from Naval Sea Systems Command for the project entitled, *Rehydration Strategies for Post-Immersion Performance in a Warm Environment*. The project continues to study the effects of prolonged immersion on a loaded march followed by high intensity intermittent exercise and the simplest approach to rehydration to optimize performance in warm conditions. The results will provide important information for Special Warfare operators and Navy Divers regarding the effects of dehydration on performance. **Riana Pryor**, Assistant Professor of Exercise and Nutrition Sciences, is Co-Investigator.



Kimberly Naus, Director of CAT Client Services, received additional funding for her award from the NYS Justice Center for the Protection of People with Special Needs entitled, *TRAID 2022 One-Time GF Payment*. The additional funds will be used to purchase a 3-D printer to support the integration of device fabrication and increased telehealth devices at Regional TRAIID Centers.



Ekaterina Noyes, Professor of Epidemiology and Environmental Health, and **Guan Yu**, Assistant Professor of Biostatistics, are Co-Is on a continuation award from the Agency for Healthcare Research and Quality (PI: Sharon Hewner, Nursing) for the project entitled, *Implementing Personalized Cross-sector Transitional Care Management to Promote Care Continuity, Reduce Low Value Utilization, and Reduce the Burden of Treatment for High-need, High-cost Patients (HNHC)*. The project will continue to study whether identifying HNHC patients at the point of transition between care settings, coupled with enhanced communication through an interoperable shared care plan, will facilitate referrals to care management, improve continuity, and reduce reliance on low-value care.





Gregory Wilding, Professor and Chair of Biostatistics, is Co-I on a new award from the National Institute of Allergy and Infectious Diseases/NIH (PI: Jonathan Lovell, Biomedical Engineering) for the project entitled, *Developing a Multi-Valent Subunit Particle Vaccine Against Tuberculosis*. The project will design a vaccine with TB antigens using a next-generation adjuvant system and will benchmark the vaccine against the established BCG vaccine.



Guan Yu, Assistant Professor of Biostatistics, is Co-I on the continuation of an award from the National Institute of Dental & Craniofacial Research/NIH (PI: Jill Kramer, Oral Biology) for the project entitled, *Analysis of MyD88-mediated Immune Activation in Sjogrens Syndrome Pathogenesis*. The study seeks to identify the tissue-specific contributions of MyD88 and the mediated signaling networks that govern pSS disease pathogenesis. Insights gained by the study will reveal novel mechanisms that govern chronic inflammation in pSS and pathways that may be targeted therapeutically, in pSS and other autoimmune diseases.

In This Issue

In the News: Congratulations to the Following Awardees 1

Grant Clinic 2

NIH Funding Opportunities

Request for Applications (RFA) 3

Program Announcements Reviews in an Institute (PAR) 7

Foundation Funding Opportunities

Robert Wood Johnson Foundation 8

DOD Funding Opportunities..... 9

UB Funding Opportunities 9

Individual Actions for Sustainability 9

Grant Clinic

GENERAL NOTICE

Request for Information

[NOT-DA-22-052](#) – Inviting Input on NIDA’s Racial Equity Initiative Action Plan

NIDA seeks comments on the draft outline for its Racial Equity Initiative Action Plan from diverse stakeholders, including scientific experts, health care providers, patients and family members, advocacy groups, other federal agencies, and non-governmental scientific, professional, and healthcare organizations. The Action Plan can be accessed at: [NIDA Racial Equity Initiative Action Plan](#). Responses must be submitted electronically to REIFeedback@nida.nih.gov by April 30, 2022

[NOT-CA-22-060](#) – Potential of Wearable Devices in Cancer Research and Care

The NCI is soliciting input on the use and development of wearable technologies for cancer diagnosis, treatment, and treatment follow-up. Please refer to the Notice for relevant topics. Responses must be submitted electronically to NCIWearablesRFI@mail.nih.gov by 11:59 pm on May 2, 2022.

NOTICE OF INTENT TO PUBLISH

[NOT-CA-22-061](#) (R34); [NOT-CA-22-062](#) (U34) - Clinical Trial Optional

FOAs for Cancer Prevention and Control Clinical Trials Planning Grant Program

The National Cancer Institute intends to promote a new initiative to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. The FOAs are expected to be published in Spring 2022 with an expected application due date in the Summer of 2022.

[NOT-CA-22-077](#) (R01, Clinical Trial Optional)

Research to Understand and Address the Survivorship Needs of Individuals Living with Advanced Cancer

The goal of this RFA, which will be released by NCI, is to enhance observational and interventional efforts to better understand and address the survivorship needs of individuals living with likely incurable cancers. The FOA is expected to be released in Spring 2022, with an expected first application due date in September 2022.

NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-DA-22-004](#) – Epidemiology of Drug Abuse

NIDA encourages applications that enhance the understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse and addiction across individuals, families, communities, and diverse population groups. **For funding consideration, applicants must include NOT-DA-22-004 in box 4B of the SF424 R&R form.** This notice applies to due dates from June 5, 2022 – September 8, 2025.

[NOT-CA-22-070](#) – Administrative Supplements for Examining Patterns of Tobacco and Cannabis Use

NCI will provide supplemental funding to current grantees for studies that address patterns of tobacco and cannabis use as a target for cancer prevention and control. Studies should collect new and/or analyze existing data on patterns of tobacco and cannabis use in adults and/or youth, especially among unrepresented, underserved, and/or vulnerable groups. **For funding consideration, applicants must include NOT-CA-22-070 in box 4B of the SF424 R&R form. Submissions must be received by May 26, 2022.**

NIH Funding Opportunities

NIH Funding Opportunities: Request for Applications (RFA)

MAY 2022 DUE DATES

[RFA-MH-22-170](#) (R01); [RFA-MH-22-171](#) (R21) - Clinical Trial Optional

Advancing communication strategies to support future HIV vaccine use

This FOA invites applications that will advance novel health communication research designed to inform and support acceptance and uptake of future vaccines that protect against HIV.

Application Due Date: May 10, 2022

[RFA-OD-22-002](#) (U01, Clinical Trial Not Allowed)

Center for Rapid Surveillance of Tobacco (CRST) to Assess Changes in Use Behaviors, Product Marketing, and the Marketplace

This FOA solicits applications for CRSTs to assess changes in use behaviors, product marketing, and the marketplace to better understand the rapidly evolving tobacco landscape in the United States. The CRST will support time-sensitive data acquisition strategies, data harmonization, data synthesis and analysis, and reporting activities on emerging and current tobacco use. **Application Due Date:** May 18, 2022

JUNE 2022 DUE DATES

[RFA-CA-22-020](#) (U01, Clinical Trial Optional)

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health

This FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. **Application Due Date:** June 17, 2022

[RFA-HS-22-001](#) (R18)

Reducing Racial and Ethnic Healthcare Disparities in Chronic Conditions by Dissemination and Implementation of Patient Centered Outcomes Research

AHRQ seeks applications to disseminate and implement patient-centered outcomes research (PCOR) findings into innovative, evidence-based interventions to reduce healthcare disparities in chronic health conditions. **Application Due Date:** June 17, 2022

JULY 2022 DUE DATES

[RFA-CA-22-015](#) (U54, Clinical Trial Optional)

Cancer Control Research in Persistent Poverty Areas

The NCI invites applications for the Persistent Poverty Initiative. The goal is to provide resources to support the time and effort of transdisciplinary teams, in collaboration with institutions, clinics, and communities/tribes, to develop a cancer prevention and control research program and provide support to early-career investigators. The focus is on serving populations living in persistent poverty areas. **Application Due Date:** July 6, 2022

[RFA-OD-22-003](#) (U54, Clinical Trial Not Allowed)

Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science

The overall objective of CASEL is scientific coordination and logistics and operations management of research projects and programs that can inform the FDA Center for Tobacco Products CTP in its tobacco product regulatory activities. **Application Due Date:** July 14, 2022

[RFA-OD-22-004](#) (U54, Clinical Trial Optional)

Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act

The overall TCORS program objective is to conduct programs of multidisciplinary research that will inform the manufacture, distribution, and marketing of tobacco products related to the regulatory authority of the Food and Drug Administration Center for Tobacco Products. **Application Due Date:** July 14, 2022

AUGUST 2022 DUE DATES

[RFA-DA-23-002](#) (R01, Clinical Trial Required)

Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users

This FOA supports research that addresses limitations in understanding how to ensure all people who use drugs and are at risk for, or living with, HIV have rapid access to high quality substance use disorder treatment and HIV care services, including Pre-exposure prophylaxis (PrEP). **Application Due Date:** August 11, 2023

[RFA-DA-23-009](#) (R21, Clinical Trial Not Allowed)

Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery

NIDA encourages exploratory and developmental research to better understand the role of social connectedness and/or loneliness in prevention, treatment and recovery from substance use disorders (SUDs). **Application Due Date:** August 15, 2022

[RFA-DA-23-010](#) (R34, Clinical Trial Optional)

Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery

This FOA encourages pilot work and preliminary research to support preparation for large-scale, rigorous trials examining strategies to address social connectedness and/or loneliness in order to prevent or treat SUDs or enhance recovery. **Application Due Date:** August 15, 2022

[RFA-RM-22-019](#) (DP2, Clinical Trial Optional)

NIH Director's New Innovator Award Program

The [New Innovator Award Program](#) supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. **Application Due Date:** August 19, 2022.

SEPTEMBER 2022 DUE DATES

[RFA-CA-22-003](#) (R61, Clinical Trial Not Allowed)

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research

This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. **Application Due Date:** September 22, 2022

NOVEMBER 2022 DUE DATES

[RFA-MD-22-008](#) (R01, Clinical Trials Optional)

Understanding and Addressing Misinformation among Populations that Experience Health Disparities

This initiative seeks to stimulate multi-level research (see [NIMHD Research Framework](#)) to understand and mitigate the harmful impacts of misinformation and disinformation among populations that experience health disparities and to inform public health practice. Examples include COVID-19, HIV/AIDS, STIs, vaccines, genetic testing, cancer, and tobacco use and cessation, among others.

Application Due Date: November 13, 2022

MULTIPLE DUE DATES

[RFA-NS-19-043 \(K99/R00\)](#) clinical trial not allowed

[RFA-NS-19-044 \(K99/R00\)](#) independent clinical trial required

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity

The BRAIN Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space. **Application Due Dates:** June 8, 2022; October 11, 2022

NCI's Informatics Technology for Cancer Research Program FOAs (Clinical Trial Optional):

[RFA-CA-22-021](#) **Development of Innovative Informatics Methods and Algorithms** (R21)

[RFA-CA-22-022](#) **Early-Stage Development of Informatics Technologies** (U01)

[RFA-CA-22-023](#) **Advanced Development of Informatics Technologies** (U24)

[RFA-CA-22-024](#) **Sustained Support for Informatics Technologies** (U24)

The program supports the development of critical tools and resources to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities.

Application Due Dates: June 14, 2022, and November 17, 2022

[RFA-HL-23-018](#) (R21)

Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research

This mechanism supports research relevant to the NHLBI mission ([Strategic Vision | NHLBI, NIH](#)) using the existing biospecimen collections that are stored in the Biorepository. Descriptions and access to the available biospecimen collections and associated datasets can be found at the NHLBI Biospecimen and Data Repository Information Coordinating Center (BioLINCC) website at www.biolincc.nhlbi.nih.gov. **Applications Due:** June 21, 2022; October 19, 2022; June 20, 2023; October 19, 2023; June 20, 2024; October 21, 2024.

[RFA-DK-20-032](#) (R34 Clinical Trial Required)

Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care

The FOA is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES.

Application Due Dates: June 22, 2022; June 22, 2023.

[RFA-HL-22-010](#) (K01 Independent Clinical Trial Required)

[RFA-HL-22-011](#) (K01 Independent Clinical Trial Not Allowed)

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research

This FOA invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations.

Application Due Dates: October 13, 2022; February 14, 2023; October 13, 2023; and February 13, 2024.

[RFA-MH-22-140](#) (R01); [RFA-MH-22-141](#) (R21) – Clinical Trial Not Allowed

Understanding Suicide Risk and Protective Factors among Black Youth

These FOAs encourage research that is designed to identify neurobiological, behavioral, social, and structural/systemic mechanisms underlying risk and protective factors for suicide among Black youth, with consideration for identification of novel targets for future development of prevention and intervention efforts.

Application Due Dates: October 19, 2022, and June 20, 2023

[RFA-EB-21-001](#) (R01 Clinical Trial Optional)

Technology Development to Reduce Health Disparities

This announcement encourages applications to develop medical devices, imaging systems, robotic systems, biomaterial interfaces, synthetic biological systems, mathematical and modeling solutions, and other technologies to address the healthcare needs of populations that experience health disparities.

Application Due Dates: January 26, 2023, and January 26, 2024

[RFA-HL-23-004](#) (R35 Clinical Trial Optional)

NHLBI Outstanding Investigator Award (OIA)

This award provides long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards. The OIA supports a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. **Application Due Dates:** February 15, 2023; February 15, 2024

[RFA-HL-23-005](#) (R35 Clinical Trial Optional)

NHLBI Emerging Investigator Award (EIA)

The purpose of this award is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators who are currently PD/PIs on at least two NHLBI R01-equivalent awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. **Application Due Dates:** February 15, 2023; February 15, 2024

[RFA-DA-22-037](#) (R01 Clinical Trial Optional)

[RFA-DA-22-038](#) (R21 Clinical Trial Optional)

Accelerating the Pace of Drug Abuse Research Using Existing Data

This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV.

Application Receipt Dates: Multiple dates, see announcement. **Expiration Date:** November 16, 2024

[RFA-DA-22-040](#) (R01 Clinical Trial Optional)

High Priority HIV and Substance Use Research

This FOA supports high priority research at the intersection of HIV and substance use and invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment, and cure of HIV among people who use drugs (PWUD).

Application Due Dates: Multiple Dates; see announcement. **Expiration Date:** February 16, 2024

[RFA-DA-23-021](#) (R43/R44 Clinical Trial Optional)

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)

This FOA encourages SBIR grant applications directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders and/or stimulant use disorders. Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics) and (2) medical therapeutic and diagnostic devices, including software as a medical device.

Application Due Dates: Multiple Dates; see announcement. **Expiration Date:** February 15, 2025

NIH Funding Opportunities: Program Announcements Reviews in an Institute (PAR)

[PAR-22-156](#) (R01); [PAR-22-157](#) (R34), Clinical Trial Optional

Alcohol Health Services Research

NIAAA seeks applications that focus on research in alcohol health services can address the treatment gap for individuals with alcohol use disorder who do not receive formal treatment from which they may benefit. closing the treatment gap for individuals with alcohol use disorder.

R01 Application Due Dates: June 5, 2022; October 5, 2022; February 5, 2023

R34 Application Due Dates: June 16, 2022; October 16, 2022; February 16, 2023

[PAR-22-158](#) (R01); [PAR-22-159](#) (R34) – Clinical Trial Required

Alcohol Treatment and Recovery Research

These FOAs, released by NIAAA, focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including medications development, precision medicine, behavioral therapies, and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.

R01 Application Due Dates: June 5, 2022; October 5, 2022; February 5, 2023

R34 Application Due Dates: June 16, 2022; October 16, 2022; February 16, 2023

[PAR-22-161](#) (U01, Clinical Trial Not Allowed)

Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts

NCI seeks to support initiating and building the next generation of population-based cancer epidemiology cohorts to address specific knowledge gaps in cancer etiology and survivorship. Specifically, it will support methodological work necessary to initiate and build cancer epidemiology cohorts that can address critical scientific gaps.

Application Due Dates: Multiple dates; please refer to the FOA; **Expiration Date:** March 1, 2025

[PAR-22-133](#) (P50, Clinical Trial Optional)

NIDA Research Center of Excellence Grant Program

This FOA will provide support for research Centers that 1) conduct drug abuse and addiction research in any area of NIDA's mission, (2) have outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers in the NIDA research fields. **Application Due Dates:** September 27, 2022; September 25, 2023; and September 24, 2024

[PAR-22-126](#) (R21, Clinical Trial Not Allowed)

Technology Development Research for Establishing Feasibility and Proof of Concept

Applications to this FOA should propose technology development at a *conceptual stage*, not yet supported by any proof-of-concept-data, in order to demonstrate feasibility of the proposed technology and/or establish the most likely path to successful development. Studies should be for innovative exploratory technology development predicated on an explicitly described broad need or challenge in biomedical research.

Application Due Dates: Standard Dates Apply; **Expiration Date:** May 8, 2025

[PAR-22-127](#) (R01, Clinical Trial Not Allowed)

Focused Technology Research and Development

The goal of this FOA is to support the development of technologies with demonstrated proof-of-concept that have remaining significant technical challenges to full implementation and broad utility. The project focus should be on advancing the technology to a stage that demonstrates its potential for broad utility in biomedical research. **Application Due Dates:** Standard Dates Apply; **Expiration Date:** May 8, 2025

[PAR-22-145](#) (R01, Clinical Trial Optional)

Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities

This FOA supports research that examines the impact of leveraging Health IT to reduce disparities in access to and utilization of health care services, quality of care, patient-clinician communication, and health outcomes for populations that experience health disparities in the U.S. Applicants are strongly encouraged to assess social determinants of health using measures available in the Social Determinants of Health Collection of the PhenX Toolkit (www.phenxtoolkit.org), as appropriate.

Application Due Dates: Standard Dates Apply; **Expiration Date:** May 8, 2025

Foundation Funding Opportunities

Robert Wood Johnson Foundation

[RTHS Program](#)

Research in Transforming Health and HealthCare Systems

The program supports policy-relevant, community-engaged research that helps improve the affordability of care for communities most impacted by structural racism, inequities, and discrimination. The Foundation seeks proposals for research and policy analysis projects that examine the design, implementation, and/or impact of local, state, and/or national policies related to the affordability of high-quality, equitable care. Studies may include people's ability to: afford health insurance; pay for healthcare services (even with insurance); pay for transportation; childcare; and other services that in turn affect access to medical care.

Application Due Dates: June 24, 2022 – Brief Proposal. November 15, 2022 – Invited Proposal

Department of Defense Funding Opportunities

Dept. of the Army – USAMRAA

[W81XWH-22-PRCRP-BHSA](#)

Behavioral Health Science Award

This award intends to advance behavioral health cancer science and fill gaps in the understanding of survivorship, including investigations into the psychological health and well-being of those affected by cancer (e.g., patients, family members). Applications may propose behavioral science that examines quality-of-life studies, decision-making and/or cognitive function research, development and testing of educational interventions, and symptom management (e.g., toxicity of treatment, palliative care, psychological distress, and anxiety).

Application Due Dates: Pre-Application – July 12, 2022. Application – August 2, 2022

[W81XWH-22-PRCRP-IA](#)

Idea Award

The Idea Award supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research that are *relevant to active-duty Service Members, Veterans, other military beneficiaries,*

and the American public. Cancers or circumstances with cancer risk that may affect the Service Members' support system (military families) are of special importance.

Application Due Dates: Pre-Application – May 25, 2022. Invited Application – September 7, 2022

[W81XWH-22-PRCRP-IPA](#)

Impact Award

This mechanism supports hypothesis-driven, high impact research. The intent of the Impact Award mechanism is to fund **mature** research projects that specifically focus on critical scientific or clinical cancer issues, which have the potential to make a major **near-term** impact on at least one of the FY22 PRCRP Topic Areas. Applications must include preliminary data to support feasibility of the study.

Application Due Dates: Pre-Application – May 25, 2022. Invited Application – September 7, 2022

University at Buffalo Funding Opportunities

UB's Translational Pilot Studies Program has released its [Spring 2022 Pilot Studies RFP](#). The program seeks proposals for innovative, high-impact clinical-translational science projects that will turn observations in the laboratory, clinic or community into interventions that improve the health of individuals/populations. Letters of Intent are due **May 16th by 9:00am**. An information session will be held via Zoom on May 9th at 12 pm. Register for the session [here](#).

Individual Actions for Sustainability



Take the 2022 WNY Earth Day Challenge

1. Sign-up
2. Participate in the Challenge Activities throughout April
3. Submit your Challenge Activities
4. Share your Challenge Activities with Others

For more information, please visit [WNY Earth Day Challenge](#)

For more information on RAS services, visit our website at sphhp.buffalo.edu/ras